Effect of C5a on expression of thrombomodulin in endothelial cells in vitro

OBJECTIVE: To investigate the effect of C5a on the expression of thrombomodulin (TM) in human umbilical vein endothelial cells (HUVECs)

Bibliographische Detailangaben
Veröffentlicht in:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue. - 1998. - 21(2009), 3 vom: 12. März, Seite 168-71
1. Verfasser: Fang, Wei (VerfasserIn)
Weitere Verfasser: Guo, Zhen-hui, Zhang, Bao-quan, Wu, Xiao-feng, Li, Ping, Lv, Feng-lin, Su, Lei
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2009
Zugriff auf das übergeordnete Werk:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Schlagworte:English Abstract Journal Article Research Support, Non-U.S. Gov't RNA, Messenger Thrombomodulin Complement C5a 80295-54-1
LEADER 01000caa a22002652 4500
001 NLM187011060
003 DE-627
005 20250210061727.0
007 tu
008 231223s2009 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0623.xml 
035 |a (DE-627)NLM187011060 
035 |a (NLM)19278588 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Fang, Wei  |e verfasserin  |4 aut 
245 1 0 |a Effect of C5a on expression of thrombomodulin in endothelial cells in vitro 
264 1 |c 2009 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 11.05.2010 
500 |a Date Revised 12.03.2009 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To investigate the effect of C5a on the expression of thrombomodulin (TM) in human umbilical vein endothelial cells (HUVECs) 
520 |a METHODS: HUVECs cultured in vitro were stimulated with C5a for 8, 12, 16, 20 hours in a concentration of 200 microg/L, and also with different concentrations of 100, 200, 300 microg/L for 12 hours respectively. The levels of both mRNA and protein expression of TM was detected by real-time polymerase chain reaction (PCR) and Western blotting respectively, and the dose and time dependent effects of C5a on the expression of TM were evaluated 
520 |a RESULTS: C5a down-regulated the TM expression at both protein and mRNA level. The down-regulation was time-dependent [(93.11+/- 1.57) x10(-2) , (71.05+/-3.39)x10(-2), (65.48+/-4.28)x10(-2), (62.69+/-4.03)x10(-2)at protein level and (301.71+/-80.40)x10(-6), (38.29+/-20.24)x10(-6), (8.82+/-2.66)x10(-6), (7.05+/-0.80)x10(-6) at mRNA level, all P<0.05] and dose-dependent [(113.25+/-3.97)x10(-2), (80.18+/-2.56)x10(-2), (73.22+/- 4.36)x10(-2) at protein level and (401.77+/-20.46)x10(-6), (31.12+/-3.51)x10(-6), (18.19+/-1.46)x10(-6) at mRNA level , all P<0.05]. When concentration of C5a at 300 microg/L was used to stimulate HUVECs for longer than 12 hours, the lowering of TM at protein level was slowed down obviously. And concentration of C5a at 200 microg/L was used to stimulate HUVECs for 12 hours, the lowering of TM at mRNA level was slowed down obviously 
520 |a CONCLUSION: C5a can depress the gene expression of TM, and then affect the protein's translation. By this means, C5a can lead to hypercoagulability and inflammatory injuries in sepsis 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a RNA, Messenger  |2 NLM 
650 7 |a Thrombomodulin  |2 NLM 
650 7 |a Complement C5a  |2 NLM 
650 7 |a 80295-54-1  |2 NLM 
700 1 |a Guo, Zhen-hui  |e verfasserin  |4 aut 
700 1 |a Zhang, Bao-quan  |e verfasserin  |4 aut 
700 1 |a Wu, Xiao-feng  |e verfasserin  |4 aut 
700 1 |a Li, Ping  |e verfasserin  |4 aut 
700 1 |a Lv, Feng-lin  |e verfasserin  |4 aut 
700 1 |a Su, Lei  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue  |d 1998  |g 21(2009), 3 vom: 12. März, Seite 168-71  |w (DE-627)NLM098227793  |x 1003-0603  |7 nnns 
773 1 8 |g volume:21  |g year:2009  |g number:3  |g day:12  |g month:03  |g pages:168-71 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 21  |j 2009  |e 3  |b 12  |c 03  |h 168-71